Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 13,632 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Completed Phase 2 Interventional

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer

NCT00004175
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride, conventional surgery
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Nov 11, 2026, 2:23 PM EST
Completed Phase 1 Interventional

A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer

NCT00732056
View directory record Official record
Conditions
Breast Cancer
Interventions
GRN163L
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Harvey, Illinois • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Nov 11, 2026, 2:23 PM EST
Not listed Not applicable Interventional

The ROle of Compression StocKings in Heart Failure Patients

NCT06350695
View directory record Official record
Conditions
Heart Failure，Congestive, Leg Edema, Venous Insufficiency, Venous Ulcers
Interventions
low grade compression stockings (10-15 mmHg), high grade compression stockings (20-30 mmHg)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Nov 11, 2026, 2:23 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Video-Based Education for Dermatology Patients on Systemic Corticosteroids

NCT01991236
View directory record Official record
Conditions
Chronic Inflammatory Skin Diseases
Interventions
Video, Standard Script
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Nov 11, 2026, 2:23 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea

NCT01618864
View directory record Official record
Conditions
Rosacea, Wrinkles
Interventions
Luxe
Device
Lead sponsor
Syneron Medical
Industry
Eligibility
21 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Nov 11, 2026, 2:23 PM EST
Completed Phase 2 Interventional Results available

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

NCT04365387
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 54 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
64
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 11, 2026, 2:23 PM EST
Completed Phase 2 Interventional Results available

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

NCT05188521
View directory record Official record
Conditions
Cutaneous Lichen Planus
Interventions
Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Aaron R. Mangold
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Nov 11, 2026, 2:23 PM EST
Completed Not applicable Interventional

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

NCT00049465
View directory record Official record
Conditions
Cancer
Interventions
fatigue assessment and management, management of therapy complications, psychosocial assessment and care
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
9
States / cities
Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Nov 11, 2026, 2:23 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Modifying Young Adult Skin Cancer Risk and Protective Behaviors

NCT03313492
View directory record Official record
Conditions
Melanoma and Other Malignant Neoplasms of Skin
Interventions
UV4.me2, UV4.me, E-Pamphlet
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 25 Years
Enrollment
1,746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
New Brunswick, New Jersey • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Nov 11, 2026, 2:23 PM EST
Terminated Phase 1 Interventional Results available

KZR-261 in Subjects With Advanced Solid Malignancies

NCT05047536
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumor
Interventions
KZR-261
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 11, 2026, 2:23 PM EST
Completed Phase 2 Interventional Results available

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

NCT00240071
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Avastin, Hormonal therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Nov 11, 2026, 2:23 PM EST
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis
Interventions
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Denver, Colorado • Gainesville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 11, 2026, 2:23 PM EST
Recruiting Phase 2 Interventional

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

NCT07287098
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Imlunestrant, Goserelin, Tamoxifen 20 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
37
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 11, 2026, 2:23 PM EST
Not listed Phase 2 Interventional

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

NCT02689921
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Exemestane, Letrozole, Anastrozole, Leuprolide Acetate, Pertuzumab, Trastuzumab
Drug
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Newnan, Georgia • Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Nov 11, 2026, 2:23 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

NCT04008784
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment
Drug
Lead sponsor
Clinical Research Center of the Carolinas
Other
Eligibility
2 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Nov 11, 2026, 2:23 PM EST
Completed No phase listed Observational

Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer

NCT00900133
View directory record Official record
Conditions
Breast Cancer
Interventions
immunoenzyme technique, laboratory biomarker analysis
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Nov 11, 2026, 2:23 PM EST
Completed Not applicable Interventional Results available

308nm Excimer Laser for Treatment of Fingernail Psoriasis

NCT02168933
View directory record Official record
Conditions
Nail Psoriasis
Interventions
308 nm excimer laser, Sham laser
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Nov 11, 2026, 2:23 PM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Lipidome and Microbiome Profile of Acne

NCT02713607
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Nov 11, 2026, 2:23 PM EST
Recruiting Phase 2 Interventional

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

NCT06771544
View directory record Official record
Conditions
Melanoma, Melanoma Stage III, Melanoma (Skin), Melanoma Stage IV
Interventions
Pembrolizumab, Cyclophosphamide
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Nov 11, 2026, 2:23 PM EST
Active, not recruiting Not applicable Interventional

Outcomes and Cosmesis With Whole Breast Irradiation and Boost

NCT06295744
View directory record Official record
Conditions
Early-stage Breast Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Nov 11, 2026, 2:23 PM EST
Completed Phase 4 Interventional Results available

Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris

NCT00835198
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone; Tretinoin, Tretinoin
Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Strongsville, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2011 · Synced Nov 11, 2026, 2:23 PM EST
Completed Not applicable Interventional

Internet-based System for Cancer Patients to Self-report Toxicity

NCT00578006
View directory record Official record
Conditions
Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer, Ovarian Cancer, Breast Cancer, Bladder Cancer
Interventions
Questioners, STAR website
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,007 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Nov 11, 2026, 2:23 PM EST
Completed Not applicable Interventional Results available

The Role of Skin Care Regimen in Skin Health

NCT03497130
View directory record Official record
Conditions
Itching, Xerosis
Interventions
skin care regimen
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Nov 11, 2026, 2:23 PM EST
Terminated Not applicable Interventional

7T MRI Scan for the Early Detection of Melanoma Brain Metastases

NCT04941430
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Magnetic Resonance Imaging using 7 Tesla MRI
Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 11, 2026, 2:23 PM EST